Navidea Biopharmaceuticals (NYSE:NAVB) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB) in a note issued to investors on Monday. The brokerage set a “sell” rating on the stock.

Navidea Biopharmaceuticals Price Performance

Shares of Navidea Biopharmaceuticals stock opened at $0.05 on Monday. The stock has a market cap of $5.00 million, a price-to-earnings ratio of -0.17 and a beta of 1.57. The firm’s 50-day moving average is $0.07 and its 200 day moving average is $0.09. Navidea Biopharmaceuticals has a 1 year low of $0.02 and a 1 year high of $0.35.

Navidea Biopharmaceuticals (NYSE:NAVB) last announced its quarterly earnings results on Friday, August 11th. The company reported ($0.03) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Navidea Biopharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Allred Capital Management LLC raised its position in Navidea Biopharmaceuticals by 78.4% in the 2nd quarter. Allred Capital Management LLC now owns 293,838 shares of the company’s stock worth $27,000 after buying an additional 129,100 shares during the last quarter. Renaissance Technologies LLC raised its position in Navidea Biopharmaceuticals by 264.5% in the 1st quarter. Renaissance Technologies LLC now owns 238,133 shares of the company’s stock worth $62,000 after buying an additional 172,800 shares during the last quarter. Finally, State Street Corp raised its position in Navidea Biopharmaceuticals by 1,631.1% in the 2nd quarter. State Street Corp now owns 412,743 shares of the company’s stock worth $38,000 after buying an additional 388,900 shares during the last quarter. Hedge funds and other institutional investors own 15.75% of the company’s stock.

Navidea Biopharmaceuticals Company Profile

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.